item 7.  management's discussion and analysis of financial condition and results of operations the following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the description of the company's business and reportable segments in item 1 above. this discussion contains forward-looking statements that involve risks and uncertainties. our actual results may differ materially from those discussed in forward-looking statements. factors that might cause a difference include, but are not limited to, those discussed under "cautionary note regarding forward-looking statements" below and in "risk factors" in part i, item 1a of this form 10-k. references herein to the "company", "we", "us", or "our" refer to walgreens boots alliance, inc. and its subsidiaries from and after the effective time of the reorganization on december 31, 2014 and, prior to that time, to its predecessor walgreen co. and its subsidiaries, and in each case do not include unconsolidated partially-owned entities, except as otherwise indicated or the context otherwise requires.
introduction on december 31, 2014, walgreens boots alliance, inc. ("walgreens boots alliance") became the successor to walgreen co. ("walgreens") pursuant to a merger to effect a reorganization of walgreens into a holding company structure (the "reorganization"), with walgreens boots alliance becoming the parent holding company. pursuant to the reorganization, walgreens became a wholly owned subsidiary of walgreens boots alliance, a delaware corporation formed for the purposes of the reorganization, and each issued and outstanding share of walgreens common stock converted on a one-to-one basis into walgreens boots alliance common stock. also on december 31, 2014, following the completion of the reorganization, walgreens boots alliance completed the acquisition of the remaining 55% of alliance boots gmbh ("alliance boots") that walgreens did not previously own (the "second step transaction") in exchange for Â£3.133 billion in cash and 144.3 million shares of walgreens boots alliance common stock. alliance boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the second step transaction. for financial reporting and accounting purposes, walgreens boots alliance was the acquirer of alliance boots. the consolidated financial statements (and other data, such as prescriptions filled) reflect the results of operations and financial position of walgreens and its subsidiaries for periods prior to december 31, 2014 and of walgreens boots alliance and its subsidiaries for periods from and after the effective time of the reorganization on december 31, 2014.
on october 27, 2015, walgreens boots alliance entered into an agreement and plan of merger with rite aid corporation ("rite aid") and victoria merger sub, inc., a wholly-owned subsidiary of walgreens boots alliance (the "merger agreement"), pursuant to which we agreed, subject to the terms and conditions thereof, to acquire rite aid, a drugstore chain in the united states with 4,550 stores in 31 states and the district of columbia as of august 27, 2016. the merger agreement was approved by rite aid stockholders in february 2016. the transaction is expected to close in early calendar year 2017, subject to regulatory approvals and other customary closing conditions.
comparability as a result of the completion of the second step transaction on december 31, 2014, there are a number of items that affect comparability of reported results. prior to december 31, 2014, our operations were within one reportable segment that included the results of the retail pharmacy usa division and corporate costs, along with the full consolidated results of walgreens boots alliance development gmbh ("wbad"), a global sourcing enterprise formed by walgreens and alliance boots, and equity earnings from alliance boots. following the completion of the reorganization and the second step transaction on december 31, 2014, we now report results in three segments. segmental reporting includes the allocation of synergy benefits, including wbad's results, and the combined corporate costs for periods subsequent to december 31, 2014. we have determined that it is impracticable to allocate historical results to the current segmental presentation. accordingly, our retail pharmacy usa segment results for periods prior to december 31, 2014 include all corporate costs of walgreens, the full consolidated results of wbad and equity income from walgreens' pre-merger 45% interest in alliance boots.
the completion of the second step transaction on december 31, 2014 also means that results for the twelve month period ended august 31, 2016 include the results of alliance boots on a fully consolidated basis, while the twelve month period ended august 31, 2015 includes the results of alliance boots for eight months (january through august 2015) on a fully consolidated basis and as equity income from walgreens' pre-merger 45% interest in alliance boots for four months (september through december 2014).
- 32 -
twelve month period-over-period comparisons of results require consideration of the foregoing factors and are not directly comparable.
in addition, our sales results are affected by a number of factors, including our sales performance during holiday periods and during the cough, cold and flu season; foreign currency fluctuations; significant weather conditions; timing of our own or competitor discount programs and pricing actions; levels of reimbursement from governmental agencies and other third party payers; and general economic conditions in the markets in which we operate.
to improve comparability, certain classification changes have been made to prior period sales, cost of sales and selling, general and administrative expenses. this change has no impact on operating income.
amerisourcebergen corporation relationship in march 2013, walgreens, alliance boots and amerisourcebergen announced various agreements and arrangements, including a ten-year pharmaceutical distribution agreement between walgreens and amerisourcebergen pursuant to which branded and generic pharmaceutical products are sourced from amerisourcebergen in the united states and an agreement which provides amerisourcebergen the ability to access generics pharmaceutical products through wbad. in may 2016, certain of these agreements were extended for three years to now expire in 2026.
in addition, in march 2013, walgreens, alliance boots and amerisourcebergen entered into agreements and arrangements pursuant to which we have the right, but not the obligation, to purchase a minority equity position in amerisourcebergen over time through open market purchases and pursuant to warrants to acquire amerisourcebergen common stock and gain associated representation on amerisourcebergen's board of directors in certain circumstances. please refer to our form 8-k filed on march 20, 2013 for more detailed information regarding these agreements and arrangements.
on march 18, 2016, we exercised warrants to purchase 22,696,912 shares of amerisourcebergen common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. on august 25, 2016, we exercised additional warrants to purchase 22,696,912 shares of amerisourcebergen common stock at an exercise price of $52.50 per share for an aggregate exercise price payment of $1.19 billion. as of august 31, 2016 we owned 56,854,867 amerisourcebergen common shares representing approximately 24% of the outstanding amerisourcebergen common stock and had designated one member of amerisourcebergen's board of directors. as of august 31, 2016, we can acquire up to an additional 8,398,752 amerisourcebergen shares in the open market and thereafter designate another member of amerisourcebergen's board of directors, subject in each case to applicable legal and contractual requirements. the amount of permitted open market purchases is subject to increase or decrease in certain circumstances.
effective march 18, 2016, we account for our investment in amerisourcebergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to our investment being classified within the operating income of our pharmaceutical wholesale segment. see note 5, equity method investments, to the consolidated financial statements included herein for further information. due to the march 18, 2016 effective date and the two-month reporting lag, our results for the 12 month period ended august 31, 2016 include approximately three and a half months of equity method income relating to our investment in amerisourcebergen. similarly, due to the timing of the transaction and the two month reporting lag, our results for the fiscal quarter ended november 30, 2016 will include approximately five weeks of equity income reflecting our increased ownership following the exercise on august 25, 2016 of the second tranche of warrants.
restructuring programs on april 8, 2015, the walgreens boots alliance board of directors approved a plan to implement a new restructuring program (the "cost transformation program") as part of an initiative to reduce costs and increase operating efficiencies. the cost transformation program implements and builds on the planned three-year, $1.0 billion cost-reduction initiative previously announced by walgreens on august 6, 2014 and includes a number of elements designed to help achieve profitable growth through increased cost efficiencies. we have identified additional opportunities for cost savings that increase the total expected cost savings of the cost transformation program by $500 million to a projected $1.5 billion by the end of fiscal 2017. significant areas of focus include plans to close approximately 200 stores across the u.s.; reorganize divisional and field operations; drive operating efficiencies; and streamline information technology and other functions. the actions under the cost transformation program focus primarily on our retail pharmacy usa segment, and are expected to be substantially completed by the end of fiscal 2017.
- 33 -
as of the date of this report, the company estimates that the cost transformation program will recognize cumulative pre-tax charges to our financial results in accordance with generally accepted accounting principles in the united states of america ("gaap") of between $1.3 billion and $1.5 billion, which  is $300 million lower than the previously estimated range of pre-tax charges at the time the cost transformation program was launched), including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. as of the date of this report, we expect to incur pre-tax charges of between $425 million and $500 million for real estate costs, including lease obligations (net of estimated sublease income); between $525 million and $575 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $350 million and $425 million for employee severance and other business transition and exit costs. we estimate that approximately 60% of the cumulative pre-tax charges will result in cash expenditures over time, primarily related to historical and future lease and other real estate payments and employee separation costs. see note 3, restructuring, to the consolidated financial statements for additional information.
the amounts and timing of all estimates are subject to change until finalized. the actual amounts and timing may vary materially based on various factors. see "cautionary note regarding forward-looking statements" below.
executive summary the following table presents certain key financial statistics for the company for fiscal 2016, 2015 and 2014.
(in millions, except per share amounts)

2016                                  2015(1)                    2014(1)
sales                                                                                                 $117,351                    $103,444                    $76,392
gross profit                                                                                            29,874                      26,753                     21,569
selling, general and administrative expenses                                                            23,910                      22,400                     17,992
operating income                                                                                         6,001                       4,668                      4,194
adjusted operating income (non-gaap measure)(2)                                                          7,208                       6,157                      4,866
earnings before interest and income tax provision                                                        5,740                       5,916                      3,713
net earnings attributable to walgreens boots alliance, inc.                                              4,173                       4,220                      1,932
adjusted net earnings attributable to walgreens boots alliance, inc. (non-gaap measure)(2)               5,009                       4,085                      3,170
net earnings per common share - diluted                                                                   3.82                        4.00                       2.00
adjusted net earnings per common share - diluted (non-gaap measure)(2)                                    4.59                        3.88                       3.28
percentage increases (decreases)

2016                   2015                    2014
sales                                                                                                  13.4                    35.4                       5.8
gross profit                                                                                           11.7                    24.0                       2.1
selling, general and administrative expenses                                                            6.7                    24.5                       2.6
operating income                                                                                       28.6                    11.3                       2.5
adjusted operating income (non-gaap measure)(2)                                                        17.1                    26.5                       0.8
earnings before interest and income tax provision                                                      (3.0     )              59.3                     (11.8   )
net earnings attributable to walgreens boots alliance, inc.                                            (1.1     )             118.4                     (24.2   )
adjusted net earnings attributable to walgreens boots alliance, inc. (non-gaap measure)(2)             22.6                    28.9                       2.2
net earnings per common share - diluted                                                                (4.5     )             100.0                     (25.1   )
adjusted net earnings per common share - diluted (non-gaap measure)(2)                                 18.3                    18.3                       0.9
- 34 -
percent to sales

2016              2015              2014
gross margin                                          25.5              25.9              28.2
selling, general and administrative expenses          20.4              21.7              23.6
(1)   see "--comparability" above.

(2)   see "--non-gaap measures" below for a reconciliation to the most directly comparable financial measure calculated in accordance with generally accepted accounting principles in the united states ("gaap").

walgreens boots alliance results of operations fiscal 2016 compared to fiscal 2015
fiscal 2016 net earnings attributable to walgreens boots alliance decreased 1.1 percent to $4.2 billion, while diluted net earnings per share decreased 4.5 percent to $3.82 compared with the prior year. the decreases reflect fluctuations in the fair value adjustments of the company's amerisourcebergen warrants and the prior year gain on the previously held equity interest in alliance boots, which was largely offset by the inclusion of alliance boots consolidated results for the entire period and an increase in operating income at retail pharmacy usa.
other income (expense) for fiscal 2016 was an expense of $261 million as compared to income of $685 million in fiscal 2015. the change in fair value of our amerisourcebergen warrants resulted in a loss of $546 million for fiscal 2016, as compared to income of $759 million for fiscal 2015. additionally, we recognized income of $268 million for fiscal year ended 2016 related to the change in accounting method for our investment in amerisourcebergen.
interest was a net expense of $596 million and $605 million in fiscal 2016 and 2015, respectively. fiscal 2016 included interest expense on notes issued during june 2016. fiscal 2015 included interest expense of $99 million related to the repayment of a portion of our long-term debt in advance of its maturity.
the effective tax rate for fiscal 2016 and 2015 was 19.4% and 19.9%, respectively. the net decrease in the effective tax rate is attributable to several factors.  first, our 2016 effective tax rate benefited from having a full-year of foreign sourced pre-tax earnings taxed at lower rates as compared to 2015, when the company had only eight months of those earnings after the second step transaction.  further, in 2016 our domestic pre-tax earnings were reduced as a result of the amerisourcebergen warrants then held by the company.  in addition, during 2016 the company benefitted from enacted tax law changes (tax rate reductions) in multiple foreign tax jurisdictions, most notably the united kingdom, which generated a $178 million tax benefit.  the company also had fewer non-deductible expenses in 2016 as compared to 2015.  these items were partly offset by the facts that in 2015 the company had a non-taxable gain on its previously held equity investment in alliance boots and recognized the benefit of a capital loss deferred tax asset, neither of which recurred in 2016.
walgreens boots alliance adjusted diluted net earnings per share (non-gaap measure)
adjusted net earnings attributable to walgreens boots alliance in fiscal 2016 increased 22.6 percent to $5.0 billion compared with the prior year. adjusted diluted net earnings per share in the fiscal year increased 18.3 percent to $4.59 compared with the prior year. the increase in adjusted net earnings and adjusted diluted net earnings per share for fiscal 2016 was primarily attributable to inclusion of alliance boots consolidated results for the entire period and an increase in operating income at retail pharmacy usa. see "--non-gaap measures" below for a reconciliation to the most directly comparable gaap measure.
fiscal 2015 compared to fiscal 2014
our results for fiscal 2015 as compared to fiscal 2014 were primarily impacted by the second step transaction which resulted in the full consolidation of alliance boots results of operations beginning december 31, 2014. for fiscal 2015, the full consolidation of alliance boots operations increased our sales by 29.4%, gross profit by 22.9%, selling general and administrative expenses by 23.1% and operating income by 18.5%, each as compared to fiscal 2014. see "--comparability" above.
- 35 -
net earnings attributable to walgreens boots alliance, inc. for fiscal 2015 were $4.2 billion, or $4.00 per share on a diluted basis as compared to $1.9 billion, or $2.00 per share on a diluted basis in fiscal 2014. the increase in diluted net earnings per share for fiscal 2015 as compared to fiscal 2014, was primarily attributable to the full consolidation of alliance boots operations from january through august 2015, a gain on our 45% previously held equity interest in alliance boots, increased sales in our retail pharmacy usa division, increased income from our warrants to acquire amerisourcebergen common stock and a lower effective income tax rate. these increases were partially offset by lower retail pharmacy usa gross margins and a higher interest expense.
as a result of acquiring the remaining 55% interest in alliance boots on december 31, 2014, our previously held 45% interest was remeasured to fair value, resulting in a gain of $563 million in fiscal 2015. the fair value of the previously held equity interest in alliance boots was determined using the income approach methodology. the fair value measurement of the previously held equity interest is based on significant inputs not observable in the market. the fair value estimates for the previously held equity interest are based on (a) projected discounted cash flows, (b) historical and projected financial information, and (c) synergies including cost savings, as relevant, that market participants would consider when estimating the fair value of the previously held equity interest in alliance boots. see note 7. acquisitions, to the consolidated financial statements for additional information.
other income (expense) for fiscal 2015 was income of $685 million as compared to expense of $481 million in fiscal 2014. the change in fair value of our amerisourcebergen warrants resulted in recording income of $759 million and $366 million in fiscal 2015 and 2014, respectively. the increase in fair value was primarily attributed to the change in the price of amerisourcebergen's common stock. in addition, we recorded $20 million and $19 million in fiscal 2015 and 2014, respectively, of other income relating to the amortization of the deferred credit associated with the initial value of the walgreens warrants. we have also recorded a loss of $94 million in fiscal 2015 on derivative contracts that were not designated as accounting hedges. the losses primarily relate to foreign currency forward contracts entered into in consideration of the delivery of foreign cash consideration related to the second step transaction. fiscal 2014 results also included a loss of $866 million related to the alliance boots call option. upon the amendment and immediate exercise of the call option to acquire the remaining 55% ownership of alliance boots, we were required to compare the fair value of the amended option with the book value of the original option. the fair value of the amended option was estimated to be zero based on its valuation as a financial instrument without regard for its strategic value. the reduction in value was primarily due to the shorter duration of the amended option and the appreciation since the original valuation in the price of walgreens stock used as partial consideration for the purchase of the remaining 55% ownership interest in alliance boots.
interest was a net expense of $605 million and $156 million in fiscal 2015 and 2014, respectively. the increase in fiscal 2015 interest expense is primarily due to the notes we issued to fund a portion of the cash consideration payable in connection with the second step transaction and to subsequently refinance substantially all of alliance boots' outstanding borrowings following completion of the second step transaction. additionally, in fiscal 2015 we repaid a portion of our long-term debt in advance of its maturity resulting in additional net interest expense of $99 million.
the effective tax rate for fiscal 2015 and 2014 was 19.9% and 42.9%, respectively. the decrease in the fiscal 2015 effective tax rate as compared to fiscal 2014 is primarily attributable to recording discrete tax benefits related to previously unrecognized capital loss deferred tax assets as a result of recognizing capital gain income from fiscal 2015 and anticipated future period sale-leaseback transactions. in addition, as a result of our acquisition of the remaining 55% interest in alliance boots that we did not previously own, our annual effective tax rate decreased due to incremental foreign source income taxed at lower rates and additional favorable permanent book-tax differences. also as a result of the acquisition, we recognized a non-recurring tax benefit that also lowered our annual effective tax rate. in addition, we recognized other, net discrete tax benefits in the current fiscal year.
- 36 -
results of operations by segment retail pharmacy usa as a result of the completion of the second step transaction, the company ceased recording equity earnings in alliance boots as of december 31, 2014. as such, the fiscal year ended august 31, 2015 includes equity income from walgreens' pre-merger 45% interest in alliance boots for four months (september through december 2014).
(in millions, except location amounts)

2016                     2015                       2014
sales                                                      $83,802                    $80,974                    $76,392
gross profit                                                22,323                     21,822                     21,569
selling, general and administrative expenses                17,918                     18,247                     17,992
operating income                                             4,405                      3,890                      4,194
adjusted operating income (non-gaap measure)(1)              5,357                      5,098                      4,866
number of prescriptions(2)                                   740.1                      723.2                      698.9
30-day equivalent prescriptions(2)(3)                        928.5                      893.8                      856.4
number of locations at period end                            8,184                      8,182                      8,309
percentage increases (decreases)

2016                   2015                     2014
sales                                                               3.5                      6.0                     5.8
gross profit                                                        2.3                      1.2                     2.1
selling, general and administrative expenses                       (1.8     )                1.4                     2.6
operating income                                                   13.2                     (7.2     )               2.5
adjusted operating income (non-gaap measure)(1)                     5.1                      4.8                     0.8
comparable store sales(4)(5)                                        3.8                      6.4                     4.9
pharmacy sales                                                      5.5                      8.2                     7.9
comparable pharmacy sales(4)(5)                                     6.0                      9.3                     6.8
retail sales                                                       (0.3     )                1.9                     2.1
comparable retail sales(4)(5)                                      (0.3     )                1.5                     2.0
comparable number of prescriptions(2)(4)(5)                         2.3                      3.5                     1.8
comparable 30-day equivalent prescriptions(2)(3)(4)(5)              4.0                      4.6                     3.9
percent to sales

2016              2015              2014
gross margin                                          26.6              26.9              28.2
selling, general and administrative expenses          21.4              22.5              23.6
(1)   see "--non-gaap measures" below for a reconciliation to the most directly comparable gaap measure and related disclosures.

(2)   includes immunizations.

(3)   includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. this adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

(4)   the fiscal year ended august 31, 2016 figures include an adjustment to remove february 29, 2016 results due to the leap year.

(5)   comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or subject to a natural disaster in the past twelve months. relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. the method of calculating comparable sales varies across the retail industry. as a result, our method of calculating comparable sales may not be the same as other retailers' methods.

sales fiscal 2016 compared to fiscal 2015
the retail pharmacy usa division's sales for fiscal 2016 increased by 3.5% to $83.8 billion. sales increased primarily due to higher comparable store sales, which were up 3.8% in fiscal 2016 driven by growth in medicare part d prescriptions, partially offset by the impact from the sale of a majority interest in our infusion business in fiscal 2015. we operated 8,184 locations (8,175 drugstores) as of august 31, 2016, compared to 8,182 locations (8,173 drugstores) a year earlier.
- 37 -
pharmacy sales increased by 5.5% in fiscal 2016 and represented 67.4% of the division's sales. in fiscal 2015, pharmacy sales were up 8.2% and represented 66.1% of the division's sales. comparable pharmacy sales increased 6.0% in fiscal 2016 compared to an increase of 9.3% in fiscal 2015. the effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 1.9% in fiscal 2016 versus a reduction of 1.8% in fiscal 2015. the effect of generics on division sales was a reduction of 1.1% in fiscal 2016 compared to a reduction of 1.0% for fiscal 2015. third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.4% of prescription sales for fiscal 2016 compared to 96.8% for fiscal 2015. the total number of prescriptions (including immunizations) filled in fiscal 2016 was 740.1 million compared to 723.2 million in fiscal 2015. prescriptions (including immunizations) adjusted to 30-day equivalents were 928.5 million in fiscal 2016 versus 893.8 million in fiscal 2015.
retail sales decreased 0.3% in fiscal 2016 and were 32.6% of the division's sales. in comparison, fiscal 2015 retail sales increased 1.9% and comprised 33.9% of the division's sales. comparable retail sales decreased 0.3% in fiscal 2016 compared to an increase of 1.5% in fiscal 2015. the decrease in comparable retail sales growth in the current fiscal year was primarily due to weakness in consumables and general merchandise, which was partially offset by increased sales in health and wellness, and photo categories.
operating income fiscal 2016 compared to fiscal 2015
retail pharmacy usa division's operating income for fiscal 2016 increased 13.2% to $4.4 billion. the increase is primarily due to higher pharmacy volume and lower selling, general and administrative expenses as a percentage of sales.
gross margin as a percent of sales was 26.6% in fiscal 2016 compared to 26.9% in fiscal 2015. pharmacy margins were negatively impacted in the current fiscal year by lower third-party reimbursements. the decrease in pharmacy margins was partially offset by the favorable impact of procurement efficiencies. retail margins were negatively impacted in the current period primarily from performance in seasonal, consumables and general merchandise categories, partially offset by performance in health and wellness, beauty and photo categories.
selling, general and administrative expenses as a percentage of sales were 21.4% in fiscal 2016 compared to 22.5% in fiscal 2015. as a percentage of sales, expenses in the current period were lower primarily due to increased efficiencies and cost controls associated with the cost transformation program.
adjusted operating income (non-gaap measure) fiscal 2016 compared to fiscal 2015
retail pharmacy usa division's adjusted operating income for fiscal 2016 increased 5.1% to $5.4 billion. the increase is primarily due to higher pharmacy volume and lower selling, general and administrative expenses as a percentage of sales. see "--non-gaap measures" below for a reconciliation to the most directly comparable gaap measure.
sales fiscal 2015 compared to fiscal 2014
the retail pharmacy usa division's sales for fiscal 2015 increased by 6.0% to $81.0 billion. sales increased primarily due to higher comparable store sales, which were up 6.4% in fiscal 2015. we operated 8,182 locations (8,173 drugstores) as of august 31, 2015, compared to 8,309 locations (8,207 drugstores) a year earlier. prior year's locations included 91 infusion and respiratory services facilities in which we sold a majority interest in fiscal 2015.
pharmacy sales increased by 8.2% in fiscal 2015 and represented 66.1% of the division's sales. in fiscal 2014, pharmacy sales were up 7.9% and represented 64.2% of the division's sales. comparable pharmacy sales increased 9.3% in fiscal 2015 compared to an increase of 6.8% in fiscal 2014. the effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 1.8% in fiscal 2015 versus a reduction of 1.3% in fiscal 2014. the effect of generics on division sales was a reduction of 1.0% in fiscal 2015 compared to a reduction of 0.7% for fiscal 2014. third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 96.8% of prescription sales for fiscal 2015 compared to 96.5% for fiscal 2014. the total number of prescriptions (including immunizations) filled in fiscal 2015 was 723.2 million compared to 698.9 million in fiscal 2014. prescriptions (including immunizations) adjusted to 30-day equivalents were 893.8 million in fiscal 2015 versus 856.4 million in fiscal 2014.
- 38 -
retail sales increased 1.9% in fiscal 2015 and were 33.9% of the division's sales. in comparison, fiscal 2014 retail sales increased 2.1% and comprised 35.8% of the division's sales. comparable retail sales increased 1.5% in fiscal 2015 compared to an increase of 2.0% in fiscal 2014. the increase in comparable retail sales in fiscal 2015 as compared to fiscal 2014 was primarily attributed to an increase in basket size partially offset by lower customer traffic.
operating income fiscal 2015 compared to fiscal 2014
retail pharmacy usa division's operating income for fiscal 2015 decreased 7.2% to $3.9 billion. the decrease is primarily due to having equity earnings in alliance boots for four months in the current year versus twelve months in the comparable period and current year costs related to the cost transformation program.
gross margin as a percent of sales was 26.9% in fiscal 2015 compared to 28.2% in fiscal 2014. pharmacy margins were negatively impacted in the current fiscal year by lower third-party reimbursements; an increase in medicare part d mix; the strategy to continue driving 90-day prescriptions at retail; and the mix of specialty drugs, which carry a lower margin percentage. the decrease in pharmacy margins was partially offset by additional brand-to-generic drug conversions compared with the prior fiscal year. retail margins were positively impacted in fiscal 2015 primarily from the non-prescription drug, beauty and beverage and snack categories partially offset by the electronics category.
selling, general and administrative expenses as a percentage of sales were 22.5% in fiscal 2015 compared to 23.6% in fiscal 2014. as a percentage of sales, expenses in fiscal 2015 were lower primarily due to store labor efficiencies partially offset by higher costs related to the cost transformation program.
adjusted operating income (non-gaap measure) fiscal 2015 compared to fiscal 2014
retail pharmacy usa division's adjusted operating income for fiscal 2015 increased 4.8% to $5.1 billion. the increase is primarily due to higher sales and lower selling, general and administrative expenses as a percentage of sales partially offset by having four months of equity earnings in alliance boots in fiscal 2015 versus twelve months in fiscal 2014 and lower gross margins. see "--non-gaap measures" below for reconciliation to the most directly comparable gaap measure.
retail pharmacy international the businesses included in our retail pharmacy international division were acquired as part of the second step transaction. the retail pharmacy international division's results, including the increases in sales, gross profit, selling, general and administrative expenses and operating income for fiscal 2016 as compared to the comparable prior year was primarily impacted by the second step transaction, which resulted in the full consolidation of alliance boots results of operations beginning december 31, 2014. accordingly, the results for this segment for fiscal 2016 include the results of alliance boots on a fully consolidated basis, while fiscal 2015 results include only eight months (january through august 2015) on a fully consolidated basis, and such results are not directly comparable. results include the effects of foreign currency exchange rates, including the british pound, euro, chilean peso and mexican peso. to improve comparability, certain classification changes have been made to prior period results. this change has no impact on operating income. see item 7a quantitative and qualitative disclosure about market risk, foreign currency exchange rate risk for further information on currency risk.
(in millions, except location amounts)

2016                      2015                  2014
sales                                                      $13,256                       $8,657          na gross profit                                                 5,432                        3,452          na selling, general and administrative expenses                 4,403                        3,043          na operating income                                             1,029                          409          na adjusted operating income (non-gaap measure)(1)              1,155                          616          na number of locations at period end                            4,673                        4,582          na
- 39 -
percentage increases
(decreases)

2016                2015
sales                                                               53.1           na gross profit                                                        57.4           na selling, general and administrative expenses                        44.7           na operating income                                                   151.6           na adjusted operating income (non-gaap measure)(1)                     87.5           na comparable store sales(2)                                             na           na comparable store sales in constant currency(2)(3)                     na           na pharmacy sales                                                      46.2           na comparable pharmacy sales(2)                                          na           na comparable pharmacy sales in constant currency(2)(3)                  na           na retail sales                                                        57.1           na comparable retail sales(2)                                            na           na comparable retail sales in constant currency(2)(3)                    na           na percent to sales

2016               2015              2014
gross margin                                          41.0                39.9        na selling, general and administrative expenses          33.2                35.1        na na   not applicable

(1)   see "--non-gaap measures" below for a reconciliation to the most directly comparable gaap measure and related disclosures.

(2)   comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. the method of calculating comparable sales varies across the retail industry. as a result, our method of calculating comparable sales may not be the same as other retailers' methods.

(3)   operating results reported in u.s. dollars are affected by foreign currency exchange rate fluctuations. we use the term "constant currency" to represent results that have been adjusted to exclude foreign currency impact. foreign currency impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the u.s. dollar. this impact is calculated by translating current period results at the currency exchange rates used in the comparable period in the prior year, rather than the exchange rates in effect during the current period. see "--non-gaap measures" below.

pharmaceutical wholesale the businesses included in our pharmaceutical wholesale division were acquired as part of the second step transaction. the pharmaceutical wholesale division's results, including the increases in sales, gross profit, selling, general and administrative expenses and operating income, for fiscal 2016 as compared to the comparable prior year was primarily impacted by the second step transaction, which resulted in the full consolidation of alliance boots results of operations beginning december 31, 2014. accordingly, the results for this segment for fiscal 2016 include the results of alliance boots on a fully consolidated basis, while fiscal 2015 results include only eight months (january through august 2015) on a fully consolidated basis, and such results are not directly comparable. results include the effects of foreign currency exchange rates, including the british pound, euro and turkish lira. see item 7a quantitative and qualitative disclosure about market risk, foreign currency exchange rate risk for further information on currency risk.
(in millions)

2016                  2015                 2014
sales                                                     $22,571               $15,327        na gross profit                                                2,131                 1,486        na selling, general and administrative expenses                1,589                 1,110        na operating income                                              579                   376        na adjusted operating income (non-gaap measure)(1)               708                   450        na
- 40 -
percentage increases
(decreases)

2016                         2015
sales                                                          47.3           na gross profit                                                   43.4           na selling, general and administrative expenses                   43.2           na operating income                                               54.0           na adjusted operating income (non-gaap measure)(1)                57.3           na comparable sales(2)                                              na           na comparable sales in constant currency(2)(3)                      na           na percent to sales

2016               2015              2014
gross margin                                           9.4                 9.7        na selling, general and administrative expenses           7.0                 7.2        na na   not applicable

(1)   see "--non-gaap measures" below for a reconciliation to the most directly comparable gaap measure and related disclosures.

(2)   comparable sales are defined as sales excluding acquisitions and dispositions.

(3)   operating results reported in u.s. dollars are affected by foreign currency exchange rate fluctuations. we use the term "constant currency" to represent results that have been adjusted to exclude foreign currency impact. foreign currency impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the u.s. dollar. this impact is calculated by translating current period results at the currency exchange rates used in the comparable period in the prior year, rather than the exchange rates in effect during the current period. see "--non-gaap measures" below.

non-gaap measures the following information provides reconciliations of the supplemental non-gaap financial measures, as defined under the rules of the securities and exchange commission, presented herein to the most directly comparable financial measures calculated and presented in accordance with gaap. as a global company, our operating results reported in u.s. dollars are affected by foreign currency exchange rate fluctuations because the underlying foreign currencies in which we transact change in value over time compared to the u.s. dollar; accordingly, we present certain constant currency financial information to provide a framework to assess how our businesses performed excluding the impact of foreign currency exchange rate fluctuations. we provide non-gaap financial measures, which are not calculated or presented in accordance with gaap, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with gaap. these supplemental non-gaap financial measures are presented because our management has evaluated our financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believe that the supplemental non-gaap financial measures presented provide additional perspective and insights when analyzing the core operating performance of our business from period to period and trends in our historical operating results. these supplemental non-gaap financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the gaap financial measures presented.
(in millions)

2016
retail                  retail            pharmaceutical         eliminations                     walgreens pharmacy                pharmacy                 wholesale                                              boots usa           international                                                               alliance, inc.
operating income (gaap)                                       $4,405                  $1,029                      $579         $(12              )                 $6,001
cost transformation                                              374                      29                        21                  -                             424
acquisition-related amortization                                 185                      97                        87                  -                             369
lifo provision                                                   214                       -                         -                  -                             214
acquisition-related costs                                        102                       -                         -                  -                             102
legal settlement                                                  47                       -                         -                  -                              47
asset impairment                                                  30                       -                         -                  -                              30
adjustments to equity earnings in amerisourcebergen                -                       -                        21                  -                              21
adjusted operating income (non-gaap measure)                  $5,357                  $1,155                      $708         $(12              )                 $7,208
- 41 -
(in millions)

2015
retail                   retail            pharmaceutical         eliminations                     walgreens pharmacy                 pharmacy                 wholesale                                              boots usa            international                                                               alliance, inc.
operating income (gaap)                                    $3,890                     $409                      $376         $(7               )                 $4,668
cost transformation                                           523                       19                         -                  -                             542
acquisition-related amortization                              230                      188                        67                  -                             485
lifo provision                                                285                        -                         -                  -                             285
acquisition-related costs                                      80                        -                         7                  -                              87
asset impairment                                              110                        -                         -                  -                             110
store closures and other optimization costs                    56                        -                         -                  -                              56
loss on sale of business                                       17                        -                         -                  -                              17
adjustments to equity earnings in alliance boots              (93   )                    -                         -                  -                             (93   )
adjusted operating income (non-gaap measure)               $5,098                     $616                      $450         $(7               )                 $6,157
(in millions)

2014
retail          retail                  pharmaceutical            eliminations                    walgreens pharmacy          pharmacy                wholesale                                                     boots usa          international                                                                alliance, inc.
operating income (gaap)                                    $4,194          $-                      $-                        $-                                 $4,194
acquisition-related amortization                              282                   -                        -                        -                            282
lifo provision                                                132                   -                        -                        -                            132
acquisition-related costs                                      82                   -                        -                        -                             82
store closures and other optimization costs                   271                   -                        -                        -                            271
gain on sale of business                                       (9   )               -                        -                        -                             (9   )
adjustments to equity earnings in alliance boots              (86   )               -                        -                        -                            (86   )
adjusted operating income (non-gaap measure)               $4,866          $-                      $-                        $-                                 $4,866
- 42 -
(in millions)

2016                  2015                   2014
net earnings attributable to walgreens boots alliance, inc. (gaap)                                 $4,173                 $4,220               $1,932
adjustments to operating income:
cost transformation(1)                                                                                424                    542                    -
acquisition-related amortization(1)                                                                   369                    485                  282
lifo provision(1)                                                                                     214                    285                  132
acquisition-related costs(1)                                                                          102                     87                   82
legal settlement(1)                                                                                    47                      -                    -
asset impairment(1)                                                                                    30                    110                    -
adjustments to equity earnings in amerisourcebergen(1)                                                 21                      -                    -
store closures and other optimization costs(1)                                                          -                     56                  271
loss (gain) on sale of business(1)                                                                      -                     17                   (9   )
adjustments to equity earnings in alliance boots(1)                                                     -                    (93   )              (86   )
total adjustments to operating income                                                               1,207                  1,489                  672
adjustments to other income (expense):
change in fair market value of amerisourcebergen warrants(1)                                          517                   (779   )             (385   )
net investment hedging (gain) loss(1)                                                                  12                    111                    -
impact of change in accounting method for amerisourcebergen equity investment(1)                     (268   )                  -                    -
gain on previously held equity interest(1)                                                              -                   (563   )                -
alliance boots call option loss(1)                                                                      -                      -                  866
total adjustments to other income (expense)                                                           261                 (1,231   )              481
adjustments to interest expense, net:
early debt extinguishment(1)                                                                            -                     99                    -
prefunded interest expenses(1)                                                                         46                     42                    -
total adjustments to interest expense, net                                                             46                    141                    -
adjustments to income tax provision:
equity method non-cash tax(2)                                                                          10                     71                  180
united kingdom tax rate change(2)                                                                    (178   )                  -                    -
release of capital loss valuation allowance(2)                                                          -                   (220   )                -
tax impact of adjustments(3)                                                                         (510   )               (385   )              (95   )
total adjustments to income tax provision                                                            (678   )               (534   )               85
adjusted net earnings attributable to walgreens boots alliance, inc. (non-gaap measure)            $5,009                 $4,085               $3,170
2016(1)             2015(1)           2014(1)

diluted net earnings per common share (gaap)                                $3.82               $4.00           $2.00
adjustments to operating income                                              1.11                1.41            0.69
adjustments to other income (expense)                                        0.24               (1.17   )        0.50
adjustments to interest expense, net                                         0.04                0.14               -
adjustments to income tax provision                                         (0.62   )           (0.50   )        0.09
adjusted diluted net earnings per common share (non-gaap measure)           $4.59               $3.88           $3.28
weighted average common shares outstanding, diluted (in millions)         1,091.1             1,053.9           965.2
- 43 -
(1)   presented on a pre-tax basis. the comparable prior periods have been recast accordingly to reflect the tax impact of adjustments as a single adjustment. there has been no change in net earnings attributable to walgreens boots alliance, inc., diluted net earnings per share, adjusted net earnings attributable to walgreens boots alliance, inc. or adjusted net earnings per share from those previously reported.

(2)   discrete tax-only items.

(3)   represents the adjustment to the gaap basis tax provision commensurate with non-gaap adjustments.

liquidity and capital resources cash and cash equivalents were $9.8 billion (including $1.6 billion in non-u.s. jurisdictions) as of august 31, 2016, compared to $3.0 billion (including $1.7 billion in non-u.s. jurisdictions) at august 31, 2015. short-term investment objectives are primarily to minimize risk and maintain liquidity. to attain these objectives, investment limits are placed on the amount, type and issuer of securities. investments are principally in u.s. treasury money market funds and aaa-rated money market funds.
our long-term capital policy is to maintain a strong balance sheet and financial flexibility, reinvest in our core strategies, invest in strategic opportunities that reinforce our core strategies and meet return requirements, and return surplus cash flow to stockholders in the form of dividends and share repurchases over the long term.
cash provided by operations and the issuance of debt are the principal sources of funds for expansion, investments, acquisitions, remodeling programs, dividends to stockholders and stock repurchases. net cash provided by operating activities was $7.8 billion in fiscal 2016 compared to $5.7 billion in fiscal 2015 and $3.9 billion in fiscal 2014.
net cash used for investing activities was $3.5 billion in fiscal 2016 compared to $4.3 billion in fiscal 2015 and $1.7 billion in fiscal 2014. the exercise of the amerisourcebergen warrants used $2.4 billion of cash in the current year. the alliance boots acquisition used $4.5 billion of cash in the comparable prior year period. other business acquisitions in fiscal 2016 were $126 million compared to $371 million in the comparable prior year period. business acquisitions in the current period include the acquisition of an international beauty brand and prescription files. other business acquisitions in the prior year period were primarily the purchase of prescription files.
additions to property, plant and equipment in fiscal 2016 were $1.3 billion compared to $1.3 billion in fiscal 2015 and $1.1 billion in fiscal 2014. capital expenditures by reporting segment were as follows:
2016            2015            2014

retail pharmacy usa                         $777            $951          $1,106
retail pharmacy international(1)             444             249               -
pharmaceutical wholesale(1)                  104              51               -
total                                     $1,325          $1,251          $1,106
(1)   our retail pharmacy international and pharmaceutical wholesale segments were acquired as part of the second step transaction in which we acquired the 55% of alliance boots that we did not already own on december 31, 2014. as a result of the timing of the acquisition, only eight months of capital expenditures (january through august 2015) have been reported for these divisions in fiscal 2015.

our retail pharmacy usa segment opened, relocated or acquired 107 locations in fiscal 2016 compared to 133 locations in fiscal 2015 and 268 locations in fiscal 2014. fiscal 2014 acquisitions included kerr drug, which contributed 76 drugstore locations as well as a specialty pharmacy and a distribution center. significant retail pharmacy international capital expenditures primarily relate to investments in our stores and information technology projects. pharmaceutical wholesale capital expenditures primarily relate to investments in warehouses and operations and information technology projects.
- 44 -
additionally, investing activities for fiscal 2016 included proceeds related to sale leaseback transactions of $60 million, compared to $867 million in the comparable prior year period, and the sale of a pharmaceutical wholesale operation for $43 million compared to the $814 million sale of walgreen infusion services in the comparable prior year period.
net cash provided by financing activities in fiscal 2016 was $2.6 billion compared to net cash used for financing activities of $915 million in fiscal 2015 and $1.6 billion in fiscal 2014.  in fiscal 2016, we received proceeds from public offerings of $6.0 billion of u.s. dollar denominated debt (described below). in fiscal 2015, we received proceeds from public offerings of $8.0 billion of u.s. dollar denominated debt, approximately $2.0 billion of euro and pound sterling denominated debt and borrowed approximately $2.2 billion on a pound sterling denominated term loan which was used to refinance substantially all of alliance boots outstanding borrowings following the completion of the second step transaction and pay related fees and expenses. we repurchased shares to support the needs of the employee stock plans totaling $1.0 billion in fiscal 2016 compared to $500 million in fiscal 2015 and $705 million in fiscal 2014. proceeds related to employee stock plans were $235 million in fiscal 2016 compared to $503 million in fiscal 2015 and $612 million in fiscal 2014. cash dividends paid were $1.6 billion in fiscal 2016 compared to $1.4 billion and $1.2 billion in fiscal 2015 and 2014, respectively. we currently intend to continue to maintain a long-term dividend payout ratio target of approximately 30 to 35 percent of adjusted net earnings attributable to walgreens boots alliance.
in august 2014, the walgreens board of directors authorized the 2014 stock repurchase program (the "2014 stock repurchase program"), which authorized the repurchase of up to $3.0 billion of walgreens' (or, after the reorganization, walgreens boots alliance's) common stock prior to the program's expiration on august 31, 2016. we purchased 1.3 million shares under the 2014 stock repurchase program in fiscal 2016 at a total cost of $110 million, compared to 8.2 million shares purchased in fiscal 2015 at a total cost of $726 million. we determine the timing and amount of repurchases based on our assessment of various factors, including prevailing market conditions, alternate uses of capital, liquidity and the economic environment. as the consideration payable to rite aid stockholders will be paid in cash, we suspended activity under the 2014 stock repurchase program (other than share repurchases to offset dilution from our equity incentive plans - see part ii, item 2 below) following our entry into the merger agreement. we have repurchased, and may from time to time in the future repurchase, shares on the open market through rule 10b5-1 plans, which enable us to repurchase shares at times when we otherwise might be precluded from doing so under insider trading laws.
the company periodically borrows under its commercial paper program and may borrow under it in future periods. there were no commercial paper borrowings outstanding as of august 31, 2016 or 2015. the company had weighted average daily short-term borrowings of $14 million of commercial paper outstanding at a weighted average interest rate of 0.66% in fiscal 2016. we had weighted average daily short-term borrowings of $82 million of commercial paper outstanding at a weighted average interest rate of 0.52% in fiscal 2015.
on november 10, 2014, walgreens boots alliance and walgreens entered into a term loan credit agreement with the lenders party thereto (the "term loan agreement"), which provided walgreens boots alliance and walgreens with the ability to borrow up to Â£1.45 billion on an unsecured basis. borrowings under the term loan agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted libor plus an applicable margin based on our credit ratings. as of august 31, 2016, we have borrowed Â£1.45 billion ($1.9 billion at the august 31, 2016 spot rate of $1.31 to Â£1) under the term loan agreement. as of august 31, 2015, we had borrowed Â£1.45 billion ($2.2 billion at the august 31, 2015 spot rate of $1.54 to Â£1) under the term loan agreement.
on november 10, 2014, walgreens boots alliance and walgreens entered into a five-year unsecured, multicurrency revolving credit agreement with the lenders party thereto (the "revolving credit agreement"), which has available credit of $3.0 billion, of which $500 million is available for the issuance of letters of credit. borrowings under the revolving credit agreement bear interest at a fluctuating rate per annum equal to, at our option, the alternate base rate or the reserve adjusted libor, in each case, plus an applicable margin calculated based on our credit ratings. as of august 31, 2016, there were no borrowings or letters of credit issued pursuant to the revolving credit agreement.
total upfront fees related to the term loan agreement and revolving credit agreement were $14 million. we pay a facility fee to the financing banks to keep these lines of credit active.
walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all obligations of walgreens boots alliance under the term loan agreement and the revolving credit agreement until august 10, 2015, when such guarantees were unconditionally released and discharged (as described below).
on november 18, 2014, walgreens boots alliance issued several series of unsecured, unsubordinated notes totaling $8.0 billion, with maturities ranging from 2016 to 2044. all such notes have fixed interest rates, with the exception of the $750 million notes due 2016, which were repaid in full in may 2016 and which had a floating rate based on the three month libor plus a fixed spread of 45 basis points.
- 45 -
on november 20, 2014, walgreens boots alliance issued series of unsecured, unsubordinated notes that included total pound sterling denominated debt of Â£700 million ($1.1 billion based on the november 20, 2014 exchange rate) with maturities due 2020 and 2025 and euro denominated debt of â¬750 million ($940 million based on the november 20, 2014 exchange rate) due 2026. all notes issued on november 20, 2014 have fixed interest rates. the notes issued on november 18, 2014 and november 20, 2014 are collectively referred to as the "2014 wba notes". the 2014 wba notes were, upon initial issuance, fully and unconditionally guaranteed on an unsecured and unsubordinated basis by walgreens.
on december 19, 2014, walgreens boots alliance and walgreens entered into a revolving credit agreement with the lenders party thereto (as amended, the "364-day credit agreement"). the 364-day credit agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. on july 9, 2015, the 364-day credit agreement was amended to remove walgreens as a borrower thereunder, eliminate walgreens' guarantee of all obligations of walgreens boots alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. on december 17, 2015, the company terminated the 364-day credit agreement. the 364-day credit agreement remained undrawn as of the date of termination and would have matured on december 30, 2015.
the 364-day credit agreement and the term loan agreement and revolving credit agreement described above each contain or contained (as applicable) a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants. as of august 31, 2016, we were in compliance with all such applicable covenants.
on july 9, 2015, pursuant to an indenture, dated as of july 17, 2008, between walgreens and wells fargo bank, national association, as trustee, notices of redemption were given to (i) holders of 1.800% unsecured notes due 2017 (the "2017 notes") and (ii) holders of 5.25% unsecured notes due 2019 (the "2019 notes"), in each case issued by walgreens under the indenture. as a result, on august 10, 2015 (the "redemption date"), the 2017 notes in the aggregate principal amount of $1.0 billion were redeemed in full and $750 million aggregate principal amount of the 2019 notes were redeemed. the partial redemption of the 2019 notes resulted in $250 million aggregate principal amount of 2019 notes remaining outstanding. the redemption price with respect to the 2017 notes was equal to 101.677% of the aggregate principal amount of such notes to be redeemed, plus accrued interest thereon to, but excluding, the redemption date. the redemption price with respect to the 2019 notes was equal to 111.734% of the aggregate principal amount of such notes to be redeemed, plus accrued interest thereon to, but excluding, the redemption date.
on august 10, 2015, upon the completion of the redemptions described above, the walgreens guarantees of the 2014 wba notes and the term loan agreement and the revolving credit agreement were unconditionally released and discharged in accordance with their terms.
pending rite aid transaction. the cash consideration payable to rite aid stockholders pursuant to the merger agreement described under "introduction" above is expected to be financed with a combination of cash on hand and debt financing. in connection with the merger agreement, walgreens boots alliance entered into a bridge facility commitment letter (as amended and restated, the "commitment letter") with ubs securities llc and ubs ag, stamford branch for a $12.8 billion senior unsecured bridge facility.
on december 18, 2015, walgreens boots alliance entered into a bridge term loan credit agreement with the lenders party thereto (as amended, the "bridge credit agreement") and a term loan credit agreement with the lenders party thereto (as amended, the "2015 term loan credit agreement" and, together with the bridge credit agreement, the "2015 credit agreements"). the commitment letter and the commitments contemplated thereby terminated upon walgreens boots alliance entering into the 2015 credit agreements.
the bridge credit agreement is a 364-day unsecured bridge term loan facility and had initial aggregate commitments of $7.8 billion, which may be increased by walgreens boots alliance prior to the funding of the loans thereunder by up to $2.0 billion in certain circumstances. as a result of the issuance of the notes and receipt of proceeds therefrom on june 1, 2016 and the entry into the term loan credit agreement on august 30, 2016, in each case, as described below, walgreens boots alliance reduced its commitment under the bridge credit agreement by approximately $6.0 billion and $1 billion, respectively, to approximately $0.8 billion. walgreens boots alliance can extend up to $3.0 billion of the loans under the bridge credit agreement for an additional 90-day period if desired. as of august 31, 2016, there were no borrowings under the bridge credit agreement. the 2015 term loan credit agreement is a $5.0 billion unsecured term loan facility comprising two tranches with maturities three and five years following the funding date, or, if earlier, three and five years after october 27, 2016. the obligations of the lenders party to each of the bridge credit agreement and the 2015 term loan credit agreement become effective upon the date of closing of the transactions contemplated by the merger agreement. as of august 31, 2016, there were no borrowings under the 2015 term loan credit agreement.
- 46 -
walgreens boots alliance will be the borrower under each of the 2015 credit agreements. the ability of walgreens boots alliance to request the making of loans under each of the 2015 credit agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. borrowings under each of the 2015 credit agreements will bear interest at a fluctuating rate per annum equal to, at walgreens boots alliance's option, the alternate base rate or the reserve adjusted eurocurrency rate, in each case, plus an applicable margin calculated based on walgreens boots alliance's credit ratings. upfront fees paid to date in connection with the 2015 credit agreements totaled $30 million. in addition, walgreens boots alliance will also pay to the lenders under each of the 2015 credit agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 credit agreement starting at 90 days after signing.
on june 1, 2016, walgreens boots alliance issued in an underwritten public offering $1.2 billion of 1.750% notes due 2018 (the "2018 notes"), $1.5 billion of 2.600% notes due 2021 (the "2021 notes"), $0.8 billion  of 3.100% notes due 2023 (the "2023 notes"), $1.9 billion of 3.450% notes due 2026 (the "2026 notes") and $0.6 billion of 4.650% notes due 2046 (the "2046 notes"). these notes are subject to redemption in certain circumstances. walgreens boots alliance intends to use the net proceeds from the sale of the notes to fund a portion of the cash consideration payable in connection with the merger contemplated by the merger agreement, to retire a portion of rite aid's existing debt and to pay related fees and expenses. any remaining net proceeds from the sale of the notes may also be used for general corporate purposes. in the event that such merger is not consummated on or prior to june 1, 2017 (the first anniversary of the issuance date of the notes) or if the merger agreement is terminated at any time on or prior to june 1, 2017, then walgreens boots alliance will be required to redeem in full the 2018 notes, the 2021 notes and the 2023 notes (but not the 2026 notes or 2046 notes, which will remain outstanding in accordance with their respective terms) on the date described in the applicable note at a redemption price equal to 101% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption. in addition, pursuant to the merger agreement, if the merger agreement is terminated by us or rite aid (i) due to the entry of a final order enjoining or prohibiting the merger by any antitrust authority, or (ii) following january 27, 2017 because required antitrust approvals have not been obtained or an antitrust authority has issued an injunction or order preventing the merger, we could be required to pay rite aid a termination fee of up to $650 million in certain circumstances.
on august 30, 2016, walgreens boots alliance entered into a $1.0 billion senior unsecured term loan facility with the lender party thereto (the "2016 term loan credit agreement") comprising two tranches with maturities on march 30, 2017 and one year after the funding date, respectively. the obligations of the lender under the 2016 term loan credit agreement become effective upon the date of closing of the transactions contemplated by the merger agreement. as of august 31, 2016, there were no borrowings under the 2016 term loan credit agreement.
each of the company's 2015 credit agreements and the 2016 term loan credit agreement contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, as well as other customary restrictive covenants, such restrictive covenants shall not be in effect until the funding of the loans under the applicable credit agreement.
as of october 19, 2016, the credit ratings of walgreens boots alliance were:
rating agency       long-term debt rating    commercial            outlook paper rating

fitch                   bbb                     f2             stable moody's                 baa2                    p-2            on review for downgrade standard &amp; poor's   bbb                     a-2            negative
- 47 -
in assessing our credit strength, each rating agency consider various factors including our business model, capital structure, financial policies and financial performance. there can be no assurance that any particular rating will be assigned or maintained. our credit ratings impact our borrowing costs, access to capital markets and operating lease costs. the rating agency ratings are not recommendations to buy, sell or hold our debt securities or commercial paper. each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating.
pursuant to our arrangements with amerisourcebergen, we have the right, but not the obligation, to purchase a minority equity position in amerisourcebergen over time as described under "--amerisourcebergen corporation relationship" above. as of august 31, 2016, the company owned 56,854,867 amerisourcebergen common shares representing approximately 24% of the outstanding amerisourcebergen common stock. this includes a total of approximately 11.5 million shares of amerisourcebergen that we purchased in the open market. share purchases may be made from time to time in open market transactions or pursuant to instruments and plans complying with rule 10b5-1. our ability to invest in equity in amerisourcebergen above certain thresholds is subject to the receipt of regulatory approvals.
on march 18, 2016, we exercised warrants to purchase 22,696,912 shares of amerisourcebergen common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. on august 25, 2016, we exercised additional warrants to purchase 22,696,912 shares of amerisourcebergen common stock at an exercise price of $52.50 per share for an aggregate exercise price payment of $1.19 billion. the transactions were funded using existing cash on hand. see note 5, equity method investments, to the consolidated financial statements included herein for further information.
we believe that cash flow from operations, availability under our existing credit facilities and arrangements, current cash and investment balances and our ability to obtain other financing, if necessary, will provide adequate cash funds for our foreseeable working capital needs, capital expenditures at existing facilities, dividend payments and debt service obligations for at least the next 12 months. our cash requirements are subject to change as business conditions warrant and opportunities arise. the timing and size of any new business ventures or acquisitions that we may complete may also impact our cash requirements.
see item 7a (qualitative and quantitative disclosures about market risk) below for a discussion of certain financing and market risks.
commitments and contingencies the information set forth in note 12 to our consolidated financial statements included in part ii, item 8 of this form 10-k is incorporated herein by reference.
critical accounting policies the consolidated financial statements are prepared in accordance with accounting principles generally accepted in the united states of america and include amounts based on management's prudent judgments and estimates. actual results may differ from these estimates. management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations. to the extent that the estimates used differ from actual results, however, adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary. these adjustments would be made in future periods. some of the more significant estimates include business combinations, goodwill and indefinite-lived intangible asset impairment, vendor allowances, liability for closed locations, cost of sales and inventory, equity method investments, pension and postretirement benefits and income taxes. we use the following methods to determine our estimates:
business combinations - we account for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired and liabilities assumed, including amounts attributable to noncontrolling interests, be recorded at their respective fair values at the date of acquisition. the determination of fair values of assets and liabilities acquired requires estimates and the use of valuation techniques when market value is not readily available.
for intangible assets, we generally use the income approach to determine fair value. the income approach requires management to make significant estimates and assumptions. these estimates and assumptions primarily include, but are not limited to: discount rates, terminal growth rates, royalty rates, forecasts of revenue, operating income, depreciation, amortization and capital expenditures. the discount rates applied to the projections reflect the risk factors associated with those projections.
- 48 -
although we believe our estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on the determination of the fair value of the intangible assets acquired.
judgment is also required in determining the intangible asset's useful life.
goodwill and indefinite-lived intangible asset impairment - goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. as part of our impairment analysis for each reporting unit, we determine fair value for each reporting unit. this determination includes estimating the fair value using both the income and market approaches. the income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows and discount rates. the market approach estimates fair value using comparable marketplace fair value data from within a comparable industry grouping.
the determination of the fair value of the reporting units and the allocation of that value to individual assets and liabilities within those reporting units requires us to make significant estimates and assumptions. these estimates and assumptions primarily include, but are not limited to: the selection of appropriate peer group companies, control premiums appropriate for acquisitions in the industries in which we compete, discount rates, terminal growth rates, forecasts of revenue, operating income, depreciation, amortization and capital expenditures. the allocation requires analysis to determine the fair value of assets and liabilities including purchased prescription files, customer relationships, pharmacy licenses and trade names. although we believe our estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting units, the amount of any goodwill impairment charge, or both.
we also compared the sum of the estimated fair values of the reporting units to the company's fair value as implied by the market value of the company's equity and debt securities. this comparison indicated that, in total, our assumptions and estimates were reasonable. however, future declines in the overall market value of the company's equity and debt securities may indicate that the fair value of one or more reporting units has declined below its carrying value.
our reporting units' fair values exceeded their carrying amounts ranging from approximately 17% to more than 116%. see note 8, goodwill and other intangible assets, to the consolidated financial statements for additional information.
indefinite-lived intangible assets are tested by comparing the estimated fair value of the asset to its carrying value. if the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized and the asset is written down to its estimated fair value.
our indefinite-lived intangible asset fair value is estimated using the relief from royalty method and excess earnings method of the income approach. these estimates can be affected by a number of factors including, but not limited to, general economic conditions, availability of market information as well as our profitability.
vendor allowances - vendor allowances are principally received as a result of purchases, sales or promotion of vendors' products. allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. those allowances received for promoting vendors' products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising incurred, with the excess treated as a reduction of inventory costs.
liability for closed locations - the liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date.
- 49 -
cost of sales and inventory - cost of sales includes the purchase price of goods and services sold, store and warehouse inventory loss, inventory obsolescence, manufacturing costs, certain direct product design and development costs and supplier rebates. in addition to product costs, cost of sales includes manufacturing costs, warehousing costs for retail operations, purchasing costs, freight costs, cash discounts and vendor allowances. cost of sales for our retail pharmacy usa segment is derived based upon point-of-sale scanning information with an estimate for shrinkage and is adjusted based on periodic inventory counts. inventories are valued at the lower of cost or market determined by the last-in, first-out ("lifo") method for the retail pharmacy usa segment and on a first-in first-out ("fifo") basis for inventory in the retail pharmacy international and pharmaceutical wholesale segments except for retail inventory in the retail pharmacy international segment, which is valued using the retail method.
equity method investments - we use the equity method to account for investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. our proportionate share of the net income or loss of these companies is included in consolidated net earnings. judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions and material purchase and sale transactions.
pension and postretirement benefits - we have various defined benefit pension plans that cover some of our foreign employees. we also have postretirement healthcare plans that cover qualifying domestic employees. eligibility and the level of benefits for these plans varies depending on participants' status, date of hire and or length of service. our pension and postretirement expenses and valuations are dependent on assumptions used by our actuaries in calculating those amounts. these assumptions include discount rates, healthcare cost trends, long-term rate of return on plan assets, retirement rates, mortality rates and other factors. in determining our long-term rate of return on plan assets assumption, we consider both the historical performance of the investment portfolio as well as the long-term market return expectations based on the investment mix of the portfolio. a change in any of these assumptions would have an effect on our projected benefit obligation and pension expense. a 25 basis point increase in the discount rate would result in a decline of $440 million to our pension benefit obligation. a 25 basis point decrease on the expected return on plan assets assumption would increase our pension expense by $24 million.
our policy is to fund our pension plans in accordance with applicable regulations. our postretirement healthcare plans are not funded.
income taxes - we are subject to routine income tax audits that occur periodically in the normal course of business. u.s. federal, state, local and foreign tax authorities raise questions regarding our tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. in evaluating the tax benefits associated with our various tax filing positions, we record a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. adjustments are made to our liability for unrecognized tax benefits in the period in which we determine the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. our liability for unrecognized tax benefits, including accrued penalties and interest, is primarily included in other long-term liabilities and current income taxes on our consolidated balance sheets and in income tax provision in our consolidated statements of earnings.
in determining our provision for income taxes, we use income, permanent differences between book and tax income, and enacted statutory income tax rates. the provision for income taxes rate also reflects our assessment of the ultimate outcome of tax audits in addition to any foreign-based income deemed to be taxable in the united states. discrete events such as audit settlements or changes in tax laws are recognized in the period in which they occur.
- 50 -
contractual obligations and commitments the following table lists our contractual obligations and commitments at august 31, 2016 (in millions):
payments due by period

total              less than              1-3 years              3-5 years                 over 5
1 year                                                                years operating leases(1)                                                    $34,089                 $3,066                 $5,798                 $5,035                $20,190
purchase obligations(2):                                                 3,108                  2,922                    176                     10                      -
open inventory purchase orders                                           2,077                  2,077                      -                      -                      -
real estate development                                                    401                    351                     50                      -                      -
other corporate obligations                                                630                    494                    126                     10                      -
short-term borrowings and long-term debt*(3)                            19,150                    323                  2,553                  4,832                 11,442
interest payment on short term borrowings and long-term debt(3)          6,723                    590                  1,121                  1,049                  3,963
insurance*                                                                 612                    201                    168                     67                    176
retirement benefit obligations                                           1,180                     73                    127                    103                    877
closed location obligations*                                               467                     81                     95                     68                    223
capital lease obligations*(1)                                            1,270                     68                    122                    114                    966
finance lease obligations                                                1,357                     18                     35                     35                  1,269
other liabilities reflected on the balance sheet*(4)                     1,121                    147                    292                    193                    489
total                                                                  $69,077                 $7,489                $10,487                $11,506                $39,595
*   recorded on balance sheet.

(1)   amounts for operating leases and capital leases do not include certain operating expenses under these leases such as common area maintenance, insurance and real estate taxes. these expenses were $460 million for the fiscal year ended august 31, 2016.

(2)   purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including open purchase orders.

(3)   in addition, in the event that the merger contemplated by the merger agreement with rite aid is not consummated on or prior to june 1, 2017 or if the merger agreement is terminated at any time on or prior to june 1, 2017, then walgreens boots alliance will be required to redeem the certain series of notes issued on june 1, 2016 on the date described in the applicable note at a redemption price equal to 101% of the aggregate principal amount of the notes to be redeemed, plus accrued and unpaid interest from and including the date of initial issuance, or the most recent date to which interest has been paid, whichever is later, to, but excluding, the date of redemption. in addition, pursuant to the merger agreement, if the merger agreement is terminated by us or rite aid (i) due to the entry of a final order enjoining or prohibiting the merger by any antitrust authority, or (ii) following january 27, 2017 because required antitrust approvals have not been obtained or an antitrust authority has issued an injunction or order preventing the merger, we could be required to pay rite aid a termination fee of up to $650 million in certain circumstances. see "liquidity and capital resources" above.

(4)   includes $302 million ($59 million in less than 1 year, $168 million in 1-3 years, $75 million in 3-5 years and none over 5 years) of unrecognized tax benefits recorded under accounting standards codification topic 740, income taxes.

the information in the foregoing table is presented as of august 31, 2016 and accordingly does not reflect obligations under agreements we entered into after that date.
off-balance sheet arrangements we do not have any unconsolidated special purpose entities and, except as described herein, we do not have significant exposure to any off-balance sheet arrangements. the term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.
at august 31, 2016, we have issued $391 million in letters of credit, primarily related to insurance obligations. we also had $60 million of guarantees outstanding at august 31, 2016. we remain secondarily liable on 79 leases. the maximum potential undiscounted future payments related to these leases was $340 million at august 31, 2016.
- 51 -
recent accounting pronouncements see "new accounting pronouncements" within note 2, summary of major accounting policies to the consolidated financial statements for information regarding recent accounting pronouncements.
cautionary note regarding forward-looking statements this report and other documents that we file or furnish with the sec contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management's assumptions. in addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the company's website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications. some of such forward-looking statements may be based on certain data and forecasts relating to our business and industry that we have obtained from internal surveys, market research, publicly available information and industry publications. industry publications, surveys and market research generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the expected execution and effect of our business strategies, our cost-savings and growth initiatives and restructuring activities and the amounts and timing of their expected impact, our pending merger agreement with rite aid and the transactions contemplated thereby and their possible effects, our commercial agreement with amerisourcebergen, the arrangements and transactions contemplated by our framework agreement with amerisourcebergen and their possible effects, estimates of the impact of developments on our earnings, earnings per share and other financial and operating metrics, cough, cold and flu season, prescription volume, pharmacy sales trends, prescription margins, changes in generic prescription drug prices, retail margins, number and location of new store openings, network participation, vendor, payer and customer relationships and terms, possible new contracts or contract extensions, the proposed withdrawal of the united kingdom from the european union and its possible effects, competition, economic and business conditions, outcomes of litigation and regulatory matters, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, impairment or other charges, acquisition and joint venture synergies, competitive strengths and changes in legislation or regulations. words such as "expect," "likely," "outlook," "forecast," "preliminary," "would," "could," "should," "can," "will," "project," "intend," "plan," "goal," "guidance," "target," "aim," "continue," "sustain," "synergy," "on track," "on schedule," "headwind," "tailwind," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," and variations of such words and similar expressions are intended to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the private securities litigation reform act of 1995.
these forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to, those relating to the impact of private and public third-party payers' efforts to reduce prescription drug reimbursements, fluctuations in foreign currency exchange rates, the timing and magnitude of the impact of branded to generic drug conversions and changes in generic drug prices, our ability to realize synergies and achieve financial, tax and operating results in the amounts and at the times anticipated, supply arrangements including our commercial agreement with amerisourcebergen, the arrangements and transactions contemplated by our framework agreement with amerisourcebergen and their possible effects, our equity method investment in amerisourcebergen, the occurrence of any event, change or other circumstance that could give rise to the termination, cross-termination or modification of any of our contractual obligations, the amount of costs, fees, expenses and charges incurred in connection with strategic transactions, whether the costs associated with restructuring activities will exceed estimates, our ability to realize expected savings and benefits from cost-savings initiatives, restructuring activities and acquisitions in the amounts and at the times anticipated, the timing and amount of any impairment or other charges, the timing and severity of cough, cold and flu season, changes in management's assumptions, the risks associated with governance and control matters, the ability to retain key personnel, changes in economic and business conditions generally or in particular markets in which we participate, changes in financial markets and interest rates, the risks associated with international business operations, including the risks associated with the proposed withdrawal of the united kingdom from the european union, the risk of unexpected costs, liabilities or delays, changes in vendor, customer and payer relationships and terms, including changes in network participation and reimbursement terms, risks of inflation in the cost of goods, risks associated with the operation and growth of our customer loyalty programs, competition, risks associated with new business areas and activities, risks associated with acquisitions, divestitures, joint ventures and strategic investments, including those relating to our ability to satisfy the closing conditions and consummate the pending acquisition of rite aid and related matters on a timely basis or at all, the risks associated with the integration of complex businesses, outcomes of legal and regulatory matters, including with respect to regulatory review and actions in connection with the pending acquisition of rite aid, and changes in legislation, regulations or interpretations thereof. these and other risks, assumptions and uncertainties are described in item 1a. "risk factors above and in other documents that we file or furnish with the sec. should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date the statement is made, whether as a result of new information, future events, changes in assumptions or otherwise.
- 52 -
